Physician profile
Artoon Arakel
NPI 1659484566
$1,292.66
in general payments reported to CMS, 2019-2025
11 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.61 · 2020: $133 · 2021: $193 · 2022: $176 · 2023: $490 · 2024: $139 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.42 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.12 | 2022-2024 | Vraylar |
| Astellas Pharma US INC | $231.14 | 2019-2023 | Myrbetriq |
| Novo Nordisk INC | $182.35 | 2021-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.95 | 2020-2022 | |
| Ardelyx, INC. | $108.30 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.35 | 2022-2023 | Jardiance |
| Lilly USA, LLC | $63.88 | 2023 | Mounjaro, Trulicity |
| Amgen INC. | $41.83 | 2024-2025 | Repatha, Otezla, Otezla |
| Esperion Therapeutics, INC. | $23.94 | 2021 | |
| Smith+Nephew, INC. | $16.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.80 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Artoon Arakel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.